Current projects

We encourage prospective D/P's (donor/participants) to become involved in current and future studies. If a study listed does not apply to your particular situation we still invite you to register so that we may include you in our database and contact you for future studies.

We are looking for D/P's in the following categories:

ID # Required D/P's Enrolled D/P's Remaining D/P's Inclusion Criteria
223723 62 62 0 Pre-Selected HBV Samples from Inventory with Viral Load and Genotype - Acute/Chronic stage
223722 52 52 0 Pre-Selected HBV Samples from Inventory - Recovered stage
223560 300 0 300 SARS-CoV-2 Fresh Negative Saliva Samples in collection devices (SpeciMAX and Spectrum) + NP swab remnant
223412 8 8 0 Remnant SARS-CoV-2 Positive Dry Nasal Swabs
223246 10 0 10 HIV-1 Positive Prospective Blood Collection Protocol
222843 20 35 -15 Remnant SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
222834 400 0 400 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps (INC3256573)
222391 3 0 3 Prospective Whole Blood Collection from HxV Negative D/Ps
222390 6 0 6 Prospective Whole Blood Collection from HxV Negative D/Ps
222389 3 0 3 Prospective Whole Blood Collection from HxV Negative D/Ps
222388 6 0 6 Prospective Whole Blood Collection from HxV Negative D/Ps
222240 8 8 0 HIV Positive Stability Study
221937 6 15 -9 Pre-screening protocol (HIV Viral Load)Samples to be tested in Abbott for Raquel (Cepheid) request
221566 200 200 0 SARS-CoV-2 Fresh Negative Saliva Samples in collection devices (SpeciMAX and Spectrum) + NP swab remnant
220541 100 42 58 Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16913)
220378 2 2 0 Fresh Whole Blood from Healthy D/Ps
219607 1000 3 997 COVID-19 Testing; Private Office
219245 117 116 1 Pre-Selected Syphilis Samples from Inventory
219219 22 21 1 Normal Serum and Plasma Samples for Panels_Q_16894, Q_16914 and Q_16913
219070 30 30 0 Pre-Selected COVID-19 Samples from Donors in the Convalescent Stage
219069 10 31 -21 Pre-Selected HBsAg Samples with Viral Load and Genotype from Inventory
218842 1 0 1 High Volume K2EDTA Plasma from Healthy Donors
218357 325 24 301 Prospective Healthy Subject Blood Collection Protocol
218316 22 443 -421 Pre-Selected HBsAg Samples with Viral Load and Genotype from Inventory
217883 65 68 -3 Prospective SARS-CoV-2 Negative Sample Collection Protocol (NPS and Saliva)
217882 65 12 53 Prospective SARS-CoV-2 Positive Sample Collection Protocol (NPS and Saliva)
216951 600 404 196 SARS-CoV-2 Fresh Negative Saliva Samples in collection devices (Isohelix and Spectrum)
216592 24 24 0 Female Vaginal Sample Collection Protocol for Panel Development
216395 4 2 2 Pre-Selected Positive Urine Samples from Inventory (Triple)
216393 12 7 5 Pre-Selected Positive Urine Samples from Inventory (Double)
216391 12 7 5 Pre-Selected Positive Urine Samples from Inventory (Single)
214431 16 8 8 HIV Positive Stability Study
213622 2500 0 2500 Protocol: cX8-CAB-547 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
212999 60 0 60 High Volume K2EDTA Whole Blood and Plasma from Healthy Donors
212096 6 6 0 Fresh Whole Blood from Healthy (HxV Negative) D/Ps
210724 150 117 33 Prospective SARS-CoV-2 Negative Raw Saliva Samples
210687 7 8 -1 Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load and Genotype
210071 2500 238 2262 Protocol: cX8-CAB-533 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
210031 1000 0 1000 COVID-19 Testing; Private Office
209249 102 102 0 Fresh Whole Blood from HIV and/or HCV Positive Individuals
208523 4 4 0 Customized Plasma Sample Collection Protocol
208168 1000 95 905 COVID-19 Testing; Private Office
207426 500 10 490 SARS-CoV-2 Prospective Collection (Protocol 015)
206835 1000 0 1000 COVID-19 Testing; Private Office
206253 60 20 40 High Volume K2EDTA Whole Blood and Plasma from Healthy Donors
205506 200 0 200 Urine and Saliva Matched Set from Healthy D/Ps
-100 subject collected in the morning until 9 AM
-100 subjects collected in the afternoon after 4 PM
205484 150 80 70 SARS-CoV-2 Negative Nasal Swabs from Inventory
205083 10 0 10 Prospective Urine Collection from Healthy Donors
204811 150 190 -40 SARS-CoV-2 Negative Raw Saliva Samples from Inventory
204810 40 0 40 Prospective SARS-CoV-2 Negative Raw Saliva Samples
Ship same day
204808 50 0 50 SARS-CoV-2 Negative Nasal Swabs from Inventory
204785 18 18 0 Pre-Selected K2EDTA Plasma from EBV Reactive D/Ps
204784 18 18 0 Pre-Selected K2EDTA Plasma from EBV Negative D/Ps
204778 1 1 0 Pre-Selected HCV Positive Samples with Viral Load from Inventory
204777 1 1 0 Pre-Selected HIV Samples from Inventory with Viral Load, Group and Subtype
203243 2000 0 2000 Pre-Selected HxV Negative Samples from Inventory
202732 1000 99 901 PROTOCOL 274C3 - Clinical Evaluation of the Xpert® Xpress CoV-2/Flu/RSV XC Test on the GeneXpert Dx and Infinity Systems in Laboratory and Near-Patient Testing Environment
202037 24 39 -15 Fresh Whole Blood from Healthy Individuals
201994 10 10 0 SARS-CoV-2 Negative Dry Nasal Swabs from Inventory
201792 60 0 60 High Volume K2EDTA Whole Blood and Plasma from Healthy Donors
201764 200 129 71 Vaginal Sample Collection Protocol from Symptomatic Vaginitis/Vaginosis D/Ps
201758 130 36 94 PAS-18SUST033 - Validation of the Clinical Performance of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure in Comparison with the Greiner Vacuette® K2EDTA Gel Tubes for Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
201750 200 280 -80 Prospective SARS-CoV-2 Negative Raw Saliva Samples
Ship same day
201743 21 20 1 Pre-Selected HIV-1 Positive/Reactive Pregnant Samples
201734 3 3 0 HIV-1 Positive Prospective Blood Collection Protocol:
- Three (3) D/Ps to have an HIV-1 Viral Load of:
Donor #1: 1000 copies/mL (+/- 10%)
Donor #2: 2000 copies/mL (+/- 10%)
Donor #3: 3000 copies/mL (+/- 10%)
201176 20 21 -1 Remnant SARS-CoV-2 Positive Dry Nasal Swabs
200854 400 407 -7 SARS-CoV-2 RNA Hologic Testing
200508 1000 60 940 COVID-19 Testing; Private Office
200080 40 40 0 SARS-CoV-2 Negative Nasopharyngeal Swabs from Inventory
200079 30 30 0 SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
199827 250 49 201 BDX-GSCP01 IDS-21QUICKSILVERCTGC
199479 11 11 0 Pre-Selected HCV Positive Samples with Viral Load from Inventory
199475 64 0 64 Pre-Selected RPR and TrepSure Positive Samples from Inventory
199074 24 24 0 Pre-Selected HBsAg Samples with Viral Load and Genotype from Inventory
199061 100 100 0 SARS-CoV-2 Negative Dry Nasal Swabs from Inventory
198619 2 2 0 HIV Viral Load Testing
198618 1 1 0 HCV Viral Load Testing
198399 220 134 86 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
198391 500 0 500 Prospective Healthy Subject Blood Collection Protocol
197511 20 20 0 SARS-CoV-2 Positive Serum and NPS Matched Set Samples from Inventory
197495 90 90 0 Fresh Whole Blood from Healthy (HxV Negative) D/Ps
196993 49 53 -4 Prospective SARS-CoV-2 Negative Raw Saliva Samples
Ship same day
196992 52 52 0 Prospective SARS-CoV-2 Negative Raw Saliva Samples
Ship same day
196725 9 10 -1 Prospective SARS-CoV-2 Negative Raw Saliva Samples
196666 12 12 0 Fresh Whole Blood from HIV-1 Positive Individuals from Oakland
195825 64 64 0 Pre-Selected HBsAg Serum Samples from Inventory
195801 220 0 220 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
195775 20000 1380 18620 Customer Samples kept in Biorepository from HBcT2 [JRID#93116]
195562 10000 0 10000 COVID-19 Testing; Private Office
195561 50 104 -54 SARS-CoV-2 RNA Hologic Testing
195554 200 328 -128 SARS-CoV-2 RNA Hologic Testing
194268 150 0 150 Prospective Nasal Swab Collection Protocol
194052 21 0 21 HxV Negative K2EDTA Plasma from Inventory - SRF_TBA
193266 200 142 58 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
191880 875 600 275 Prospective Healthy Subject Blood Collection Protocol
191188 10000 54 9946 COVID-19 Testing; Private Office
190737 5000 9 4991 SARS-CoV-2 Survey (PT)
184754 2542 3168 -626 Disposition of BioRepository Samples - Lav/Yellow Tubes
184026 700 542 158 SARS-CoV-2 RNA Hologic Testing
182696 1000 322 678 Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections
182007 180 180 0 Endocervical Sample Collection Protocol
181140 20 0 20 Fresh Whole Blood from HIV-1 Positive Individuals from Oakland
180183 30 7 23 Prospective SARS-CoV-2 Positive Raw Saliva Samples
180141 15 15 0 Normal Serum and Plasma Samples for Panels_Q_16847
179314 5 586 -581 Pre-Selected HBV Samples from Inventory with Viral Load
178076 130 79 51 PAS -19SUST046 - Evaluation of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure for Repeatability and Reproducibility of Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
177477 4 2 2 COVID-19 Testing - 2 Wolves Film
177081 301 282 19 Pre-Selected Negative Samples from Inventory
176628 100 1669 -1569 COVID-19 Testing; Punta Cana Doctors_Initiative
176622 10 0 10 Normal Serum Samples with Unit Back-Ups
DP willing to donate a Whole Blood Unit
176111 25 0 25 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps - SRF_6026_Q16802
175884 500 97 403 SARS-CoV-2 RNA Hologic Testing
175792 10000 116 9884 COVID-19 Testing; Tu Cara me Sue
175398 10000 552 9448 COVID-19 Testing; Crew-Royal Caribbean Cruises Ltd
175121 1000 27 973 CBC Initiative
174026 1000 120 880 COVID-19 Testing; Private Office
173505 20 20 0 SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
172886 1000 1003 -3 COVID-19 Testing; Private Office
172103 10 10 0 Prospective SARS-CoV-2 Positive Sample Collection Protocol (NPS and Saliva)
171438 1000 0 1000 COVID-19 Testing; Private Office
169711 400 398 2 SARS-CoV-2, Nasal swab, Nasopharyngeal Swab, Oropharyngeal swab and Saliva
169440 300 110 190 Remnant Pregnancy Samples
169439 100 258 -158 Remnant HSV Samples
168884 50 0 50 Evaluation of the prognostic performance of HostDx ViralSeverity to predict outcomes of SARS-CoV-2
168867 1000 282 718 COVID-19 Testing; Private Office
168630 5000 0 5000 SARS-CoV-2 by RNA (RT-PCR) Detection Testing
168264 10 10 0 SARS-CoV-2 Negative Nasal, Nasopharyngeal Swab
168078 50 2 48 Prospective COVID-19 Positive Sample Collection Protocol (NPS and Raw Saliva)
165876 30 6201 -6171 Disposition of Urine Samples, CT/GC Negative, collected before 2020
165868 1000 86 914 COVID-19 Testing; Private Office
164918 1000 270 730 COVID-19 Testing; Private Office
164264 1000 10 990 COVID-19 Testing; Private Office
164218 1000 403 597 COVID-19 Testing; Private Office
163957 1000 0 1000 COVID-19 Testing; Private Office
163925 1000 0 1000 COVID-19 Testing; Private Office
163904 1000 777 223 COVID-19 Testing; Private Office
163430 1000 315 685 COVID-19 Testing; Private Office
163200 1000 20 980 COVID-19 Testing; Private Office
162422 1000 75 925 COVID-19 Testing; Private Office
162417 35 34 1 Fresh Whole Blood from Healthy (HxV Negative) D/Ps - SRF_5868_4
161853 100 861 -761 Abbott RealTime CT/NG Testing, Cepheid_248C1& 248C3
161580 1000 13 987 COVID-19 Testing; Private Office
161059 1000 259 741 COVID-19 Testing; Private Office
160615 47 47 0 Clinical Performance of the Checkable Medical COVID-19 At-home Rapid Antibody Test and the Clarity COVIBLOCK COVID-19 IgG/IgM Antibody Test (Positive)
160614 75 90 -15 Clinical Performance of the Checkable Medical COVID-19 At-home Rapid Antibody Test and the Clarity COVIBLOCK COVID-19 IgG/IgM Antibody Test (Negative)
160588 30 30 0 Prospective SARS-CoV-2 Positive Raw Saliva Samples
159619 1000 63 937 COVID-19 Testing; Private Office
157936 1000 8 992 COVID-19 Testing; Private Office
157935 1000 44 956 COVID-19 Testing; Private Office
157934 1000 803 197 COVID-19 Testing; Private Office
156661 10000 1634 8366 COVID-19 Testing; Private Office
155679 30 302 -272 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
155371 10000 384 9616 COVID-19 Testing; Private Office
154904 10000 40 9960 COVID-19 Testing; Private Office
154667 10000 876 9124 COVID-19 Testing; Private Office
154536 1000 458 542 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 500 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
153900 10000 31306 -21306 COVID-19 Testing, Florida Department of Health
152854 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
152825 5000 87806 -82806 COVID-19 Testing
152764 9 27 -18 HCV Viral Load Testing
152672 5000 40 4960 Follow-UP_COVID-19 Testing_Blood and Nasopharyngeal Swabs
152661 1000 41 959 Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, QT00016682)
152645 24 0 24 Female Vaginal Sample Collection Protocol for Panel Development
152331 5000 1654 3346 COVID-19 Testing
151990 195 13 182 Pre-Selected CMV Positive Samples form Inventory (SRF_5628 - STING Project)
151989 195 50 145 Pre-Selected CMV Negative Samples form Inventory (SRF_5628 - STING Project)
151893 500 282 218 Fresh Whole Blood, Capillary blood, Nasopharyngeal swab and Nasal swab match set from symptomatic individuals
151886 500 285 215 Fresh Whole Blood, Capillary blood, Nasopharyngeal swab and Nasal swab match set from symptomatic individuals
151681 5000 3 4997 Refer to Processing Instructions @ Attachment Tab
151476 1 0 1 HIV Group and Subtype Testing
150014 500 64 436 Seegene Validation Collection Protocol from Male and Female Samples
149547 5000 150 4850 Refer to Processing Instructions @ Attachment Tab
TESTS TO SELECT PER LOCATION - REFER TO ATTACHMENT TAB
149472 100 69 31 HIV-2 Prospective Blood Collection Protocol - SRF_5628
149267 200 135 65 Prospective Nasopharyngeal Swab Collection- SRF_5469
148791 5000 20 4980 Refer to Processing Instructions @ Attachment Tab
146391 92 0 92 High Volume Whole Blood Collection to Evaluate The Long-Term Stability of Roche cfDNA tubes - SRF_5743
146000 520 282 238 Prospective Nasal and Nasopharyngeal Matched Swab Sample Collection Protocol
145574 5000 50 4950 Refer to Processing Instructions @ Attachment Tab
144888 195 1277 -1082 Pre-Selected Negative Samples form Inventory (SRF_5628 - STING Project (SRF_0002000))
144620 5000 29 4971 Refer to Processing Instructions @ Attachment Tab
144001 100 825 -725 Pediatric EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM):
- 50 samples from subjects with the ages of 2 through 12 years of age AND
- 50 samples from subjects with the ages of 13 through 21 years of age
- Gender: Male or Female
- Minimum Volume: 1.5 mL (1.2 mL's)
- Storage Temperature: Samples must have been frozen at -20°C or below within 2 days of collection.
143401 1500 1158 342 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 3000 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
142755 5000 50 4950 Refer to Processing Instructions @ Attachment Tab
141914 1000 7 993 HIV Initiative
141834 1500 1246 254 HIV-1 Viral Load Testing Proposal
141493 5000 30 4970 HCV Viral Load and Genotype Survey (PT)
141491 5000 12 4988 HBV Viral Load Survey (PT)
141490 5000 30 4970 HIV Viral Load Survey (PT)
141142 50 12 38 Fresh Whole Blood from Healthy (HxV Negative) D/Ps - SRF_5635
140923 5000 50 4950 Refer to Processing Instructions @ Attachment Tab
140922 5000 30 4970 Refer to Processing Instructions @ Attachment Tab
140530 5000 10 4990 Rubella IgG (AAB - PT)
140528 5000 6 4994 ToRCH (AAB - PT)
140300 1500 1500 0 HIV-1 Viral Load Testing Proposal
139409 5000 55 4945 Pregnancy (PT)
137933 5000 0 5000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
137683 930 248 682 Preeclampsia Blood Collection Protocol from Asymptomatic and Symptomatic Populations
136025 300 357 -57 EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM)
135041 100 0 100 GC/CT/MG/TV prospective collection at Budapest
134700 60 25 35 Abbott Real Time EBV and BKV Testing - SRF_5465
134182 100 80 20 HBV/Mayaro Samples from Colombia
133225 200 274 -74 Prospective HCV Positive serum collection
129688 200 123 77 EBV / EBK Samples from National Center of Urology - Tbilisi, Georgia
129538 1000 309 691 RPR Initiative
128402 1000 64 936 CBC Initiative
124266 5000 143 4857 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cote D'Ivoire
122931 5000 1485 3515 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
122654 5000 171 4829 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Swaziland
120851 140 26 114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
120409 300 84 216 Matched Prospective Collection Protocol from an HCV, HBsAg and/or RPR Positive Reactive Population
111718 1000 0 1000 Prospective Pediatric Population Blood Collection Protocol
109382 100 32 68 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
109381 300 6 294 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
108692 1000 903 97 HxV Testing Initiative
102772 50 26 24 Random Cadaveric Samples
102419 1000 425 575 Samples on hold for future shipments to China
98830 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP, Endocervical Swab, Vaginal Swab, Nasal Swab, Pharyngeal Swab, Rectal Swab, Urethral Swab and/or Urine Samples
98084 1000 562 438 CBC Qualifying Job Request
96278 5000 185 4815 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
96211 5000 0 5000 A Multi-Site, Point in Time, Prospective Blood Collection Protocol in order to obtain Samples from Pediatric D/Ps (Donor/Participants)
96055 40 1580 -1540 Hologic Panels for HIV and HCV
94841 500 1 499 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV - LGR
93116 700 734 -34 Prospective Blood Collection Protocol from D/Ps with Signs & Symptoms or at High Risk for Hepatitis
83729 10000 0 10000 A Multi-Site, Multi-Point, Prospective Blood Collection Protocol in order to Collect Infected samples from Hepatitis A Samples from Donor/Participants (D/Ps)
80997 5000 428 4572 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
79734 100 0 100 Prospective Zika Screening and Longitudinal Sample Collection Protocol
78138 300 140 160 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
78137 300 414 -114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
74811 7000 0 7000 Prospective HIV-1 Low Risk Population Blood Collection Protocol
74261 10000 0 10000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
68258 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
66495 200 225 -25 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World for Dengue
63869 1 2 -1 Negative Material for Panel Member
63868 1000 555 445 Blinded HIV/HBV/HCV Prospective Blood Collection Protocol from Guinea Bissau
56717 20000 0 20000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP , Endocervical, Vaginal, Nasal and/or Urine Samples
55075 10000 28 9972 Beta HCG Matched Set Prospective Blood Collection Protocol
54664 200 148 52 Random Cadaveric Samples
38626 300 143 157 Prospective Sample Collection of Specifically Diagnosed D/Ps with Diseases of the Liver or Related Complications:
·50 x Alcoholic liver disease
·30 x Autoimmune hepatitis
·30 x Fatty liver disease
·30 x Non-alcoholic Steatohepatitis (NASH)
·30 x Primary Biliary Cirrhosis (PBC)
27615 15000 633 14367 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World
26761 10000 482 9518 HIV Positive Time Stability Whole Blood Collection Protocol
10694 3000 2234 766 HCV Longitudinal Prospective Blood Collection Protocol
10693 3000 369 2631 HBV Multi-Point Prospective Blood Collection Protocol
8568 300 1528 -1228 Positive Plasma Units from Blood Centers Around the World (HIV, HBsAg & HCV)



BCW helps clinicians during their research process through collection sites and D/P availability. Our collection sites have been duly inspected and adhere to our Good Manufacturing Practices thus ensuring reliability during the collection process. In addition to this we provide training seminars as part of our Quality Assurance in order to maintain the level of quality that our customers are accustomed to.

You will be invited to participate in research studies for the advancement of diagnostic technologies. Participation in these studies is voluntary. Our D/P's are informed of what the research projects are about and are given an Informed Consent, which evidences their willingness to participate. In order to protect our D/P's we never divulge your identity to the research facilities thus guaranteeing D/P confidentiality.



Contact us to learn more